Systemic lupus erythematosus.

Systemic lupus erythematosus is a complex multisystem autoimmune disorder with a heterogeneous presentation and clinical course. The pathogenesis is multifactorial with evidence of genetic susceptibility, environmental triggers, and aberrancy in both the innate and adaptive immune systems. Although significant therapeutic advances have been made in recent decades, there remains a significant increase in mortality, highlighting the need for further understanding of the underlying immune mechanisms.

[1]  S. Teschner,et al.  Leflunomide: a drug with a potential beyond rheumatology. , 2010, Immunotherapy.

[2]  L. Iaccarino,et al.  Hormones, immune response, and pregnancy in healthy women and SLE patients. , 2010, Swiss medical weekly.

[3]  D. Erkan,et al.  Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? , 2010, Lupus.

[4]  A. Vasudevan,et al.  Changing worldwide epidemiology of systemic lupus erythematosus. , 2010, Rheumatic diseases clinics of North America.

[5]  D. Isenberg,et al.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. , 2010, Immunity.

[6]  R. Roubey,et al.  Use of Rituximab in the Antiphospholipid Syndrome , 2010, Current rheumatology reports.

[7]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[8]  R. Cervera.  [Therapeutic strategies in antiphospholipid syndrome]. , 2010, Reumatologia clinica.

[9]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.

[10]  J. Levy,et al.  Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  S. Pierangeli,et al.  Statins for the Treatment of Antiphospholipid Syndrome? , 2009, Annals of the New York Academy of Sciences.

[12]  Y. Shoenfeld,et al.  Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside , 2009, Lupus.

[13]  G. Hughes,et al.  The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe , 2009, Lupus.

[14]  E. Uz,et al.  Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases , 2009, Arthritis research & therapy.

[15]  C. Edwards,et al.  Anti-TNF-induced lupus. , 2009, Rheumatology.

[16]  P. Emery,et al.  Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis , 2009, Expert opinion on biological therapy.

[17]  M. Margaglione,et al.  Atherosclerosis in thrombotic primary antiphospholipid syndrome , 2009, Journal of thrombosis and haemostasis : JTH.

[18]  M. García-Carrasco,et al.  Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality , 2009, Lupus.

[19]  C. Ponticelli,et al.  Cyclosporine (CsA) in lupus nephritis: assessing the evidence. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  P. Alba.  [Lupus nephritis and pregnancy in the 21st. century]. , 2009, Revista de la Facultad de Ciencias Medicas.

[21]  B. Tom,et al.  Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus , 2008, The Journal of Rheumatology.

[22]  D. Kamen,et al.  Vitamin D in systemic lupus erythematosus , 2008, Current opinion in rheumatology.

[23]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[24]  J. Takagi,et al.  Milk fat globule EGF factor 8 in the serum of human patients of systemic lupus erythematosus , 2008, Journal of leukocyte biology.

[25]  M. Khamashta,et al.  Hydroxychloroquine: the cornerstone of lupus therapy , 2008, Lupus.

[26]  A. Scott,et al.  17beta-estradiol alters the activity of conventional and IFN-producing killer dendritic cells. , 2008, Journal of immunology.

[27]  Marta E Alarcón-Riquelme,et al.  Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci , 2008, Nature Genetics.

[28]  D. Isenberg,et al.  B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres , 2007, Annals of the rheumatic diseases.

[29]  T. Ruzicka,et al.  Topical calcineurin inhibitors in cutaneous lupus erythematosus , 2008, Archives of Dermatological Research.

[30]  D. Isenberg,et al.  Fifty years of anti-ds DNA antibodies: are we approaching journey's end? , 2007, Rheumatology.

[31]  Bi Zhou,et al.  Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. , 2007, American journal of human genetics.

[32]  M. Clowse.  Lupus activity in pregnancy. , 2007, Rheumatic diseases clinics of North America.

[33]  B. Beutler,et al.  TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity , 2007, Nature Medicine.

[34]  G. Sturfelt,et al.  Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. , 2007, Kidney international.

[35]  Elizabeth W Karlson,et al.  Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. , 2007, Arthritis and rheumatism.

[36]  J. Chapman,et al.  Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. , 2007, Seminars in arthritis and rheumatism.

[37]  P. Lipsky,et al.  Deficient CD4+CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus1 , 2007, The Journal of Immunology.

[38]  B. Namjou,et al.  The Genetics of Lupus , 2007 .

[39]  J. Ravetch,et al.  Fc-receptors as regulators of immunity. , 2007, Advances in immunology.

[40]  B. Volpe,et al.  Human lupus autoantibodies against NMDA receptors mediate cognitive impairment , 2006, Proceedings of the National Academy of Sciences.

[41]  D. Isenberg,et al.  Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[42]  Mimi Y. Kim,et al.  The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. , 2006, Arthritis and rheumatism.

[43]  O. Rekvig,et al.  Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis , 2006, Arthritis research & therapy.

[44]  P. Mudd,et al.  Regulatory T Cells and Systemic Lupus Erythematosus , 2006, Scandinavian journal of immunology.

[45]  D. Isenberg,et al.  An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. , 2006, Rheumatology.

[46]  B. Volpe,et al.  Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[47]  O. Rekvig,et al.  Cardiovascular, Pulmonary and Renal Pathology Nephritogenic Lupus Antibodies Recognize Glomerular Basement Membrane-Associated Chromatin Fragments Released from Apoptotic Intraglomerular Cells , 2006 .

[48]  G. Burmester,et al.  Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus , 2006, Arthritis research & therapy.

[49]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[50]  D. Isenberg,et al.  Systemic lupus erythematosus—2005 annus mirabilis? , 2006, Nature Clinical Practice Rheumatology.

[51]  T. Yoshio,et al.  Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[52]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[53]  M. Urowitz,et al.  Mortality in systemic lupus erythematosus. , 1987, Arthritis and rheumatism.

[54]  C. Grimaldi,et al.  Sex hormones and SLE: influencing the fate of autoreactive B cells. , 2006, Current topics in microbiology and immunology.

[55]  R. Voll,et al.  SLE--a disease of clearance deficiency? , 2005, Rheumatology.

[56]  Mimi Y. Kim,et al.  Outcomes of planned home births with certified professional midwives: large prospective study in North America , 2005, BMJ : British Medical Journal.

[57]  K. Chi-Burris,et al.  Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre‐transplant diabetes , 2005, Clinical transplantation.

[58]  Hee-Kap Kang,et al.  Very Low-Dose Tolerance with Nucleosomal Peptides Controls Lupus and Induces Potent Regulatory T Cell Subsets12 , 2005, The Journal of Immunology.

[59]  J. Kere,et al.  Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.

[60]  B. Diamond,et al.  Block and tackle: CTLA4Ig takes on lupus , 2005, Lupus.

[61]  J. Merrill.  BLyS antagonists and peptide tolerance induction , 2005, Lupus.

[62]  J. Banchereau,et al.  IFN-α Induces Early Lethal Lupus in Preautoimmune (New Zealand Black × New Zealand White)F1 but Not in BALB/c Mice1 , 2005, The Journal of Immunology.

[63]  J. Esdaile,et al.  Methotrexate in systemic lupus erythematosus , 2005, Lupus.

[64]  J. Banchereau,et al.  IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. , 2005, Journal of immunology.

[65]  D. Isenberg,et al.  Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases , 2005, Current opinion in pharmacology.

[66]  J. Harley,et al.  Genetics of human systemic lupus erythematosus: the emerging picture. , 2004, Current opinion in immunology.

[67]  A. Rahman.  Autoantibodies, lupus and the science of sabotage. , 2004, Rheumatology.

[68]  J. Salmon,et al.  Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation , 2004, Nature Medicine.

[69]  M. Aringer,et al.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. , 2004, Arthritis and rheumatism.

[70]  M. Ward.  Prevalence of physician-diagnosed systemic lupus erythematosus in the United States: results from the third national health and nutrition examination survey. , 2004, Journal of women's health.

[71]  I. Bruce,et al.  Systemic Lupus Erythematosus: An Independent Risk Factor for Endothelial Dysfunction in Women , 2004, Circulation.

[72]  L. Rönnblom,et al.  Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. , 2004, Arthritis and rheumatism.

[73]  D. Boumpas,et al.  Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients , 2004, Lupus.

[74]  D. Isenberg,et al.  Is α-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? , 2004 .

[75]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Kidney international.

[76]  J. Cameron.  The treatment of lupus nephritis , 1989, Pediatric Nephrology.

[77]  D. Isenberg,et al.  Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? , 2004, Arthritis and rheumatism.

[78]  J. Buyon,et al.  Immunohistologic evidence supports apoptosis, IgG deposition, and novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block. , 2004, Arthritis and rheumatism.

[79]  J. Attwood,et al.  Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance , 2004, Neuroradiology.

[80]  E. Fireman,et al.  Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome. , 2004, Autoimmunity reviews.

[81]  J. Schwartz,et al.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[82]  J. Buyon,et al.  Maternal autoantibodies and congenital heart block: mediators, markers, and therapeutic approach. , 2003, Seminars in arthritis and rheumatism.

[83]  V. Roschke,et al.  B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. , 2003, Arthritis and rheumatism.

[84]  V. Roschke,et al.  Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. , 2003, Arthritis and rheumatism.

[85]  D. Isenberg,et al.  The pathogenesis of systemic lupus erythematosus. , 2003, The Netherlands journal of medicine.

[86]  D. Gladman,et al.  Accrual of organ damage over time in patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[87]  G. Hughes,et al.  Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 Patients , 2003, Medicine.

[88]  M. Wener,et al.  Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[89]  C. Lau,et al.  Pathogenesis of systemic lupus erythematosus , 2003, Journal of clinical pathology.

[90]  B. Vanderhyden,et al.  Focal and Segmental Glomerulosclerosis in Mice with Podocyte-Specific Expression of Mutant α-Actinin-4 , 2003 .

[91]  E. D. De Jong,et al.  Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. , 2003, Arthritis and rheumatism.

[92]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[93]  P. Cohen,et al.  Animal models for SLE. , 2003, Current protocols in immunology.

[94]  R. Bagin,et al.  LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. , 2003, Arthritis and rheumatism.

[95]  D. Isenberg,et al.  Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. , 2003, Rheumatology.

[96]  L. Rönnblom,et al.  Systemic lupus erythematosus and the type I interferon system , 2003, Arthritis research & therapy.

[97]  S. Luo,et al.  Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[98]  D. Isenberg,et al.  An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[99]  M. Braun,et al.  Drug-induced systemic lupus erythematosus and TNF-α blockers , 2002, The Lancet.

[100]  Y. Levy,et al.  Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. , 2002, Arthritis and rheumatism.

[101]  C. Grimaldi,et al.  Estrogen alters thresholds for B cell apoptosis and activation. , 2002, The Journal of clinical investigation.

[102]  M. Walport.  Complement and systemic lupus erythematosus , 2002, Arthritis research.

[103]  D. Isenberg,et al.  Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades , 2002, Annals of the rheumatic diseases.

[104]  C. Putterman,et al.  α-Actinin Is a Cross-Reactive Renal Target for Pathogenic Anti-DNA Antibodies1 , 2002, The Journal of Immunology.

[105]  C. Putterman,et al.  Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. , 2002, Journal of immunology.

[106]  G. Ferraccioli,et al.  Drug-induced systemic lupus erythematosus and TNF-alpha blockers. , 2002, Lancet.

[107]  P. Lipsky,et al.  Immunoglobulin variable-region gene usage in systemic autoimmune diseases. , 2001, Arthritis and rheumatism.

[108]  M. Petri,et al.  Catastrophic Antiphospholipid Syndrome: Clues to the Pathogenesis from a Series of 80 Patients , 2001, Medicine.

[109]  D. Gladman,et al.  Living with lupus: a prospective pan-Canadian study. , 2001, The Journal of rheumatology.

[110]  T. Behrens,et al.  Delineating the genetic basis of systemic lupus erythematosus. , 2001, Immunity.

[111]  E. Wakeland,et al.  The genetics of lupus , 2001, Current opinion in nephrology and hypertension.

[112]  M. Monestier,et al.  Lupus anti‐DNA autoantibodies cross‐react with a glomerular structural protein: a case for tissue injury by molecular mimicry , 2001, European journal of immunology.

[113]  Y. Shoenfeld,et al.  Azathioprine therapy for patients with systemic lupus erythematosus. , 2001, Lupus.

[114]  D. Isenberg,et al.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. , 2001, The New England journal of medicine.

[115]  G. Sturfelt,et al.  Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies , 2000, Lupus.

[116]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[117]  D. D'cruz,et al.  The prevalence and associations of fatigue in systemic lupus erythematosus. , 2000, Rheumatology.

[118]  M. Zhu,et al.  Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. , 2000, Thrombosis and haemostasis.

[119]  D. Alarcón-Segovia,et al.  Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[120]  K. Blenman,et al.  Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[121]  K. Sullivan,et al.  Genetics of systemic lupus erythematosus. Clinical implications. , 2000, Rheumatic diseases clinics of North America.

[122]  J. Bach,et al.  Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. , 2000, Arthritis and rheumatism.

[123]  C. Lau,et al.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. , 2000, The New England journal of medicine.

[124]  Y Ioannou,et al.  A review of gastrointestinal manifestations of systemic lupus erythematosus. , 1999, Rheumatology.

[125]  L. Lu,et al.  Major peptide autoepitopes for nucleosome-specific T cells of human lupus. , 1999, The Journal of clinical investigation.

[126]  J. Berden,et al.  Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. , 1999, Current opinion in nephrology and hypertension.

[127]  Caroline Gordon,et al.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. , 1999, Arthritis and rheumatism.

[128]  I. Bruce,et al.  The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. , 1999, The Journal of rheumatology.

[129]  M. Ward.  Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[130]  L. Kuller,et al.  Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. , 1999, Arthritis and rheumatism.

[131]  R. Voll,et al.  Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. , 1998, Arthritis and rheumatism.

[132]  Y. Ohsugi,et al.  IL‐6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice , 1998, Clinical and experimental immunology.

[133]  Pier Paolo Pandolfi,et al.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.

[134]  R. Herrera-Esparza,et al.  Renal expression of IL-6 and TNFα genes in lupus nephritis , 1998 .

[135]  Andrew C. R. Martin,et al.  Genetic, structural and functional properties of an IgG DNA‐binding monoclonal antibody from a lupus patient with nephritis , 1998, European journal of immunology.

[136]  J. Harley,et al.  An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. , 1997, The Journal of clinical investigation.

[137]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[138]  M. Monestier,et al.  Antigen specificity of anti‐nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo , 1997, European journal of immunology.

[139]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[140]  M. Weisman,et al.  Reduction in circulating dsDNA antibody titer after administration of LJP 394. , 1997, The Journal of rheumatology.

[141]  T. Vischer,et al.  Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. , 1997, The Journal of rheumatology.

[142]  J. Renauld,et al.  Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity , 1995, Lupus.

[143]  D. Isenberg,et al.  Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. , 1995, Kidney international.

[144]  D. Gladman,et al.  Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. , 1995, The Journal of rheumatology.

[145]  P. Limburg,et al.  Prevention of relapses in systemic lupus erythematosus , 1995, The Lancet.

[146]  C. Gordon,et al.  The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. , 1995, Arthritis and rheumatism.

[147]  M. Pujol,et al.  High prevalence of platelet autoantibodies in patients with systemic lupus erythematosus , 1995, British journal of haematology.

[148]  B. Diamond,et al.  Mutational analysis of an autoantibody: differential binding and pathogenicity , 1994, The Journal of experimental medicine.

[149]  H. Dijkman,et al.  Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. , 1994, The Journal of clinical investigation.

[150]  A. Rosen,et al.  Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes , 1994, The Journal of experimental medicine.

[151]  J. Harley,et al.  A distinctive autoantibody profile in black female patients with lupus nephritis. , 1993, Arthritis and rheumatism.

[152]  M. Walport,et al.  Splenic uptake of immune complexes in man is complement-dependent. , 1993, Journal of immunology.

[153]  F. Breedveld,et al.  The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. , 1993, Clinical immunology and immunopathology.

[154]  M. Okamura,et al.  Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. , 1993, Annals of the rheumatic diseases.

[155]  R. Coffman,et al.  Mechanism and regulation of immunoglobulin isotype switching. , 1993, Advances in immunology.

[156]  F. Dove.  Drug-induced lupus , 1982 .

[157]  A. Steinberg,et al.  Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis , 1992, The Lancet.

[158]  S. Avrameas,et al.  Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. , 1991, Immunology today.

[159]  P. Limburg,et al.  Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. , 1990, Arthritis and rheumatism.

[160]  J. Sánchez-Guerrero,et al.  Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients , 1989, Medicine.

[161]  D. Wofsy,et al.  Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. , 1989, Clinical immunology and immunopathology.

[162]  C. Jacob,et al.  Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis , 1988, Nature.

[163]  H. Mcdevitt,et al.  Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. , 1988, Nature.

[164]  O. Pankewycz,et al.  Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. , 1987, Journal of immunology.

[165]  Thomas L. Rothstein,et al.  The role of clonal selection and somatic mutation in autoimmunity , 1987, Nature.

[166]  A. Todd-Pokropek,et al.  Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. , 1985, Arthritis and rheumatism.

[167]  P. Stastny,et al.  Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. , 1982, Annals of internal medicine.

[168]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[169]  M. Walport,et al.  The immunogenetics of SLE. , 1982, Clinics in rheumatic diseases.

[170]  J. Cameron,et al.  Lupus Nephritis , 1959, Clinics in rheumatic diseases.

[171]  M. Reichlin,et al.  Deposition of antibodies to a soluble cytoplasmic antigen in the kidneys of patients with systemic lupus erythematosus. , 1979, Arthritis and rheumatism.

[172]  H. Kunkel,et al.  Systemic lupus erythematosus associated with klinefelter's syndrome. , 1977, Arthritis and rheumatism.

[173]  M. Urowitz,et al.  The bimodal mortality pattern of systemic lupus erythematosus. , 1976, The American journal of medicine.

[174]  P. Schur,et al.  IMMUNOLOGICAL STUDIES CONCERNING THE NEPHRITIS OF SYSTEMIC LUPUS ERYTHEMATOSUS , 1967, The Journal of experimental medicine.

[175]  L. E. Shulman,et al.  SEROLOGIC ABNORMALITIES IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 1963, Journal of chronic diseases.

[176]  M. Merrell,et al.  Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. , 1955, Journal of chronic diseases.

[177]  W. S. Clark.  The treatment of rheumatoid arthritis. , 1949, The Medical clinics of North America.

[178]  A D GUNN,et al.  Case of Anaphylaxis after Anaesthesia , 1943, British medical journal.